ImmunoCellular Therapeutics Sees Significant Drop in Short Interest (IMUC)
ImmunoCellular Therapeutics (NYSE:IMUC) was the target of a large decrease in short interest in August. As of August 15th, there was short interest totalling 1,919,299 shares, a decrease of 7.6% from the July 31st total of 2,076,368 shares, Analyst Ratings Network.com reports. Based on an average trading volume of 242,075 shares, the days-to-cover ratio is currently 7.9 days. Currently, 3.3% of the company’s stock are short sold.
Shares of ImmunoCellular Therapeutics (NYSE:IMUC) opened at 0.95 on Thursday. ImmunoCellular Therapeutics has a 52-week low of $0.65 and a 52-week high of $4.00. The stock has a 50-day moving average of $0.95 and a 200-day moving average of $1.16. The company’s market cap is $57.6 million.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.